LAURUSLABS stock news on Anadi Algo News

Friday, May 8, 2026
DISCLAIMER: AI-generated signals are for informational purposes only. All trading and investment decisions are solely the user's responsibility.|Past performance does not guarantee future results. Trade at your own risk.|Anadi Algo is not a SEBI-registered advisor. Consult a qualified financial advisor before acting on any recommendation.|DISCLAIMER: AI-generated signals are for informational purposes only. All trading and investment decisions are solely the user's responsibility.|Past performance does not guarantee future results. Trade at your own risk.|Anadi Algo is not a SEBI-registered advisor. Consult a qualified financial advisor before acting on any recommendation.|
Stock Landing|13 matching stories

LAURUSLABS Share Price, Latest News & Sentiment

Latest AI-analyzed news for LAURUSLABS, along with saved share-price context, sentiment, quarterly filing summary, and related names in one page.

Stock Coverage Hub

LAURUSLABS News Today

Widely covered stock

The banking sector, represented by Central Bank of India, is currently seeing analyst interest for potential upside [4]. Dividend announcements can add to short-term trading dynamics within this sector.

Coverage
13
recent stories
Sources
4
distinct publishers
Bias Split
11 bullish / 2 bearish
0 neutral stories
Window
58d
recent coverage span
Saved Quote Snapshot

Laurus Labs Limited

Last Updated
7 May 2026
Price
Rs 1,204
+2.24%
52W Range
Rs 572.25 - Rs 1,223.7
exchange snapshot
PE / VWAP
PE 71.44
VWAP Rs 1,206.63
Trend Read
bullish
Bullish stack · EMA 5 > 9 > 21 > 50
Business Context
Industry: Pharmaceuticals
Sector Trail: NIFTY MIDCAP 50
Listing Date: 2016-12-19
Market Structure
F&O Eligible: Yes
Indices: NIFTY MIDCAP 50, NIFTY500 MULTICAP INDIA MANUFACTURING 50:30:20, NIFTY 200
Snapshot Source: mcp+nse
Quarterly Read

Quarter ended 31 Dec 2024

Consolidated results
What This Quarter Says

Laurus Labs has released its latest financial report. **What improved:** We can't tell what improved or weakened because we don't have past numbers to compare with. **Why it matters:** This report shows how the company is doing financially right now. Investors and the public use this information to understand the company's current health.

Revenue
Rs 1,415 cr
up 11.8% vs previous filing
Profit
Rs 90.61 cr
up 58.2% vs previous filing
EPS / Finance Cost
EPS 1.71
Finance cost Rs 57.8 cr
Filing Context
Filed 25 Jan 2025, 2:14 am
Figures are taken from the saved exchange filing, not from a live request.
Quick Reader Notes
  • Revenue this quarter: Rs 1,415 cr, up 11.8% vs previous filing.
  • Profit this quarter: Rs 90.61 cr, up 58.2% vs previous filing.
  • EPS gives a quick sense of per-share earnings: 1.71.
How To Read This

Treat this block as a saved quarter snapshot. First see whether revenue and profit are improving, then read the latest news below to judge whether recent headlines support that trend or work against it.

LAURUSLABS FAQ

Why is LAURUSLABS in the news right now?

LAURUSLABS has appeared across 13 recent stories from 4 sources, which usually means there is a real flow of fresh headlines rather than a single isolated mention.

Is LAURUSLABS coverage bullish or bearish right now?

LAURUSLABS coverage is currently leaning bullish, with 11 bullish, 2 bearish, and 0 neutral analyzed stories in the recent window.

Which themes are moving with LAURUSLABS?

Recent LAURUSLABS coverage is clustering around Pharmaceuticals and Chemicals. Related names showing up alongside LAURUSLABS include DIVISLAB, AUROPHARMA, GRANULES.

How should I use this LAURUSLABS news page?

Use this page as a coverage hub for LAURUSLABS: start with the latest headlines, then check the dominant themes, related names, and saved market context before you form a trade or watchlist view.

Workflow View

Use LAURUSLABS coverage to build a cleaner watchlist.

A stock page is most useful when it helps you slow down, compare headlines, and separate one-off noise from a repeatable setup.

This is here if you want to go deeper, not as a push.Explore Anadi
For Central Bank of India, consider a short-term 'buy the dividend' strategy today, but be prepared for potential ex-dividend price adjustment tomorrow, with risk managed by the dividend amount.|Quick check: CENTRALBK neutral (+1.7% 1d), LAURUSLABS bullish bias (+1.3% 1d).
et_markets3 days ago

Market Trading Guide: 5 stock ideas for gains up to 11% on Tuesday

The broader market is experiencing positive sentiment due to election expectations, which is influencing sector-specific movements and stock recommendations. This creates opportunities for selective trades in sectors like logistics and pharmaceuticals.

Traders should look for long opportunities in recommended stocks like ADANIPORTS and LAURUSLABS, with strict stop-losses, while avoiding or shorting stocks like CDSL if technicals align.|Quick check: ADANIPORTS bullish bias (overbought), LAURUSLABS bullish bias (+5.7% 1d).
et_markets7 days ago

Laurus Labs Q4 Results: Cons PAT increased 19% to Rs 279 crore, revenue rises 5%

The pharmaceutical sector continues to be a defensive play with growth opportunities in specialized segments like CDMO. Strong earnings from key players like Laurus Labs can bolster overall sector sentiment amidst broader market volatility.

Maintain a bullish bias on quality pharma stocks with strong earnings visibility, focusing on companies demonstrating robust growth in niche segments like CDMO, with disciplined risk management.|Quick check: LAURUSLABS neutral (-0.0% 1d), MARUTI neutral (+0.2% 1d).

Latest LAURUSLABS Stock Coverage

For AU Small Finance Bank, consider a long position if it shows strong opening momentum, with a tight stop-loss below immediate support levels.|Quick check: AUBANK bullish bias (overbought), TATACOMM bullish bias (overbought).
Consider momentum plays in these specific stocks, but set strict stop-losses due to potential volatility.|Quick check: BHEL bullish bias (overbought), NAM-INDIA bullish bias (-2.2% 1d).
Given the article's age, the market has likely priced in the immediate geopolitical concerns; focus on the long-term fundamentals of recommended stocks like Laurus Labs, Data Patterns, and Syrma SGS, but remain cautious of broader market volatility.
Market has likely priced in the initial sentiment; however, monitor policy developments and investment announcements in API manufacturing for long-term bullish plays on domestic pharma and chemical companies.
Consider short-term bullish plays on downstream chemical, pharma, and textile companies benefiting from reduced input costs until June 30th.
Given the article's age, the market has likely priced in some of this, but monitor Q4 and Q1 results of API manufacturers for sustained margin pressure; consider short-term bearish bias on API-heavy pharma stocks.
Consider accumulating HDFC Bank and Laurus Labs for long-term portfolios, aligning with brokerage recommendations for potential 10-30% returns by 2026.
Consider long positions in Sai Life Sciences and other Indian CRDMO players, watching for sustained buying interest and sector-wide momentum.
Bullish for Indian API manufacturers; consider long positions in key domestic players benefiting from export growth and PLI schemes.